#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA5046502	Physicochemical	Dissociation constant, pKa of the compound		1	ALA5046219	small-molecule physicochemical format	Scientific Literature
2.	ALA5046503	Functional	Neuroprotective activity against MPTP/probenedcic-induced DAergic neuron loss in ig dosed C57BL/6 mouse model of Parkinson's disease assessed as increase in GDNF level in SNpc pretreated with MPTP/probenecid for 32 days followed by compound addition for next 20 days and measured after 20 days by immunofluorescence analysis	Mus musculus	1	ALA5046219	organism-based format	Scientific Literature
3.	ALA5046504	Functional	Neuroprotective activity against MPTP/probenedcic-induced DAergic neuron loss in C57BL/6 mouse model of Parkinson's disease assessed as increase in GDNF level in SNpc at 1 to 2 mg/kg, ig pretreated with MPTP/probenecid for 32 days followed by compound addition for next 20 days and measured after 20 days by immunofluorescence analysis	Mus musculus	1	ALA5046219	organism-based format	Scientific Literature
4.	ALA5046505	Functional	Anti-neuroinflammation in mouse BV-2 cells assessed as inhibition of LPS-induced NO production at 1 uM preincubated for 6 hrs followed by LPS addition measured after 24 hrs by Griess reagent based assay	Mus musculus	21	ALA5046219	cell-based format	Scientific Literature
5.	ALA5046506	Binding	Inhibition of human iNOS assessed as reduction in L-[3H]-citrulline level using L-[3H]-arginine as substrate incubated for 1 hr	Homo sapiens	22	ALA5046219	single protein format	Scientific Literature
6.	ALA5046507	Binding	Inhibition of human nNOS assessed as reduction in L-[3H]-citrulline level using L-[3H]-arginine as substrate incubated for 1 hr	Homo sapiens	22	ALA5046219	single protein format	Scientific Literature
7.	ALA5046508	Binding	Inhibition of human eNOS assessed as reduction in L-[3H]-citrulline level using L-[3H]-arginine as substrate incubated for 1 hr	Homo sapiens	22	ALA5046219	single protein format	Scientific Literature
8.	ALA5046509	Binding	Selectivity ratio of IC50 for human nNOS to IC50 for human iNOS	Homo sapiens	22	ALA5046219	protein format	Scientific Literature
9.	ALA5046510	Binding	Selectivity ratio of IC50 for human eNOS to IC50 for human iNOS	Homo sapiens	22	ALA5046219	assay format	Scientific Literature
10.	ALA5046511	ADME	Effective permeability of compound in PBS buffer at pH 7.4 at 200 uM incubated for 17 hrs by PAMPA-BBB assay		10	ALA5046219	assay format	Scientific Literature
11.	ALA5046512	Binding	Binding affinity to iNOS in mouse BV-2 cells assessed as thermal stability at 1 uM measured after 3 hr by cellular ITDRF-CETSA	Mus musculus	1	ALA5046219	cell-based format	Scientific Literature
12.	ALA5046513	Binding	Binding affinity to recombinant human iNOS assessed as dissociation constant by surface plasmon resonance assay	Homo sapiens	1	ALA5046219	single protein format	Scientific Literature
13.	ALA5046514	Binding	Time dependent inhibition of human iNOS at 50 to 800 nM	Homo sapiens	1	ALA5046219	single protein format	Scientific Literature
14.	ALA5046515	Functional	Neuroprotective activity in mouse BV-2 cells assessed as reduction in cell injury at 0.1 to 10 uM preincubated for 6 hrs followed by LPS addition and measured after 24 hrs by LDH leakage assay	Mus musculus	1	ALA5046219	cell-based format	Scientific Literature
15.	ALA5046516	Functional	Neuroprotective activity in mouse BV-2 cells assessed as reduction in cell apoptosis at 0.1 to 10 uM measured after 24 hrs by by Hoechst 33258 staining based fluorescence microscopic method	Mus musculus	1	ALA5046219	cell-based format	Scientific Literature
16.	ALA5046517	Functional	Neuroprotective activity in mouse BV-2 cells assessed as reduction in cell apoptosis at 0.1 to 10 uM measured after 24 hrs by Annexin V/PI double staining base flow cytometry analysis	Mus musculus	1	ALA5046219	cell-based format	Scientific Literature
17.	ALA5046518	Functional	Neuroprotective activity in MPTP-induced C57BL/6 mouse model of Parkinson's disease assessed as increase in traction score at 1 to 2 mg/kg, po pre-administered daily for 10 days followed by MPTP challenge and measured at 4 to 72 hrs post MPTP challenge by traction test	Mus musculus	1	ALA5046219	organism-based format	Scientific Literature
18.	ALA5046519	Functional	Neuroprotective activity in MPTP/probenecid -induced C57BL/6 mouse model of Parkinson's disease at 1 to 2 mg/kg, po pretreated with MPTP/probenecid for 32 days followed by compound addition for next 20 days and measured after 52 to 54 days post MPTP challenge by traction test	Mus musculus	2	ALA5046219	organism-based format	Scientific Literature
19.	ALA5046520	Functional	Neuroprotective activity in MPTP-induced C57BL/6 mouse model of Parkinson's disease at 1 to 2 mg/kg, po pre-administered daily for 10 days followed by MPTP challenge and measured at 4 to 72 hrs post MPTP challenge by open-field test	Mus musculus	1	ALA5046219	organism-based format	Scientific Literature
20.	ALA5046521	Functional	Neuroprotective activity in MPTP-induced C57BL/6 mouse model of Parkinson's disease at 1 to 2 mg/kg, po pre-administered daily for 10 days followed by MPTP challenge and measured at 4 to 72 hrs post MPTP challenge by rotarod test	Mus musculus	1	ALA5046219	organism-based format	Scientific Literature